Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (BMY) is a healthcare company (drug manufacturers - general) based in the United States. The share price is $60.90, down 3.23% on the day, which values the company at $124.48B. Price as of 17 Nov 2026, 17:22 UTC, from Yahoo Finance.

Key facts

Share price
$60.90−3.23% today
Market value
$124.48B
P/E ratio
13.5×last 12 months
Forward P/E
9.1×
Dividend yield
4.00%
Funk Score
57/100
Against its own history
Below its usual priceusual price $81.54
200-week average
$55.3010% above

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Bristol-Myers Squibb Company in more detail

BMY trades at 13.5× its last twelve months' earnings, 9.1× next year's expected earnings, 2.5× sales. Measured against its own history, the price is 25% below what its usual multiples would imply ($81.54) — below its usual price. It sits 10% above its 200-week average of $55.30.

Over the last five fiscal years Bristol-Myers Squibb Company has compounded revenue 2.5% a year, free cash flow -0.7% a year. Its Funk Score is 57 out of 100 (financial strength 5.0, profitability 9.0, growth 2.3, value 6.7, each out of 10).

In its favour: Strong Piotroski score; High return on invested capital.

15 of the superinvestors tracked here hold BMY, including Richard Pzena (2.6% of the portfolio), Thomas Kahn (1.6% of the portfolio), Josef Lakonishok (1.1% of the portfolio).

Superinvestors holding BMY

15 of the investors tracked here report a position in their latest 13F filing.

Compare

Health Care companies of similar size

Side by side:BMY vs MDT (Bristol-Myers Squibb Company vs Medtronic)BMY vs SYK (Bristol-Myers Squibb Company vs Stryker)BMY vs MCK (Bristol-Myers Squibb Company vs McKesson)BMY vs VRTX (Bristol-Myers Squibb Company vs Vertex Pharmaceuticals)BMY vs SNY (Bristol-Myers Squibb Company vs Sanofi)

All health care companies by market valueLargest companies in the United StatesAll stocks A–Z

Bristol-Myers Squibb Company (BMY): questions and answers

What is BMY's P/E ratio?

Bristol-Myers Squibb Company trades at 13.5× its last twelve months' earnings and 9.1× next year's expected earnings. At its fiscal year-ends over the past 17 years the P/E ranged from 4.7× to 100.5×, with a median of 22.1×.

What is BMY's PEG ratio?

Bristol-Myers Squibb Company's PEG ratio is 17.39 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.

What is Bristol-Myers Squibb Company's market cap?

Bristol-Myers Squibb Company is valued at $124.48B at a share price of $60.90.

Is BMY overvalued or undervalued?

Against its own history, BMY is below its usual price: the price is 25% below the $81.54 implied by the median multiples it has traded at (price / earnings, price / sales, price / book, price / free cash flow). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is BMY above its 200-week moving average?

Yes. BMY is 10.1% above its 200-week average of $55.30. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is Bristol-Myers Squibb Company growing?

Over the last five fiscal years Bristol-Myers Squibb Company's revenue grew 2.5% a year; over ten years revenue grew 11.3% a year.

Cite this page

Funkfolio, “Bristol-Myers Squibb Company (BMY) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/BMY

Underlying data: Yahoo Finance; company filings with the SEC.